Amgen
Recent news from Amgen summarized
Published in Pharma Law Weekly, January 9th, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Amgen.
Report 1: Amgen (AMGN) announced results from a multicenter, single-arm, phase II study of AMG 706, an investigational oral targeted VEGF receptor inhibitor.
In this study, AMG 706 showed encouraging clinical activity in patients with advanced high-dose imatinib-resistant gastrointestinal stromal tumors (GIST). These data were presented in an oral session at the Connective Tissue Oncology Society (CTOS) meeting in Venice, Italy.
"AMG 706 targets tyrosine kinases, a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Law Weekly
Source: Pharma Law Weekly (2007-01-09)
More Articles from Pharma Law Weekly
- Awards
DEAM wins LiveWIRE Young Business Award 2006 - Behavior
Researchers at University of Victoria target behavior - Behavior
Scientists at University of Nevada target behavior - Business & Finance
Del Global Technologies announces fiscal 2007 first quarter financial results - Business Update
Darwin Professional Underwriters targets Tech//404 for health care organizations - Cancer Vaccines
Data from University of Pittsburgh, Pittsburgh Cancer Institute advance knowledge in cancer vaccines - More from this issue of Pharma Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
